2026 outlooks: The first wave has landed. Check out our forecasts for US PE, US VC, healthcare and EMEA.
Q3's fundraising update: Private markets pulled in $900 billion through September despite a tough fundraising year. Europe has seen a record 34% of commitments, and global dry powder is climbing, though the clock is ticking for deployment. Read more.
Turbulence settles: Aerospace and defense rebounded in Q3 with more clarity on tariffs and a new defense budget, our new report finds. Read it here. |
|
|
|
|
|
| |
|
|
| Watch: How AI is reshaping private capital (on-demand) |
|
AI has moved from theory to implementation. Some private capital firms are already reshaping how they operate. Others are actively exploring where it can drive the most value. Either way, understanding this shift is now essential to evaluating not just AI-native companies but the broader ecosystems your portfolios operate in.
In this on-demand session, you'll hear from:
- David Hefter – AI Champion for Investments, BlackRock
- Rohan Sahai – Engineering Manager, OpenAI
What they cover:
- Where AI adoption is actually showing up in enterprise workflows and decision-making (with real examples)
- How generative AI is expanding deal teams' capabilities to process information, identify patterns, and move faster
- Emerging tools, market signals, and what to watch as AI continues to evolve
Get the video |
|
|
|
|
|
| |
| For top VCs, early-stage strategy has evolved |
|
|
Through Q3, a top 15 VC firm has participated in 3.5% of all pre-seed, seed and early-stage rounds. While this figure remains in line with previous years, the total value of these rounds now accounts for a record 21% of all capital deployed at these stages—compared to 2021-2024 annual average of 14.4%.
This rising share of capital from top firms highlights shifting dynamics in early-stage venture investing. With deal sizes and valuations at record highs, large, multi-stage investors are playing an outsized role.
These firms, which we rank based on a methodology considering exit rates and future valuation growth of past investments, are leveraging their size and access to highly competitive rounds to place larger early-stage bets.
Rounds with top investor participation now command a median deal size at 2.8 times the overall venture median at the pre-seed and seed stages and 6.1 times the median for Series A and B.
As top investors' portfolio companies are equipped with significantly more capital, a distinction is growing between this unique subset of investment and the broader venture space.
Among areas targeted by this investor cohort, AI saw the most activity, accounting for 57.7% of all transactions and 60.7% of total capital deployed in Q3. Top investors also shifted attention toward industrial technology, driving a record $782.4 million in funding across 17 deals in the vertical over the quarter. Expanding defense budgets and a renewed emphasis on domestic production drove activity into the historically niche area of investment, with Castelion and Mariana Minerals closing headline rounds.
View more data in our Q3 Emerging Tech Indicator, which tracks seed and early-stage rounds from the most successful investors, revealing the products and technologies best positioned to alter the venture landscape. This report breaks down which startups these firms are funding and what it tells us about where venture is headed next.
|
|
Best,
Ben Riccio
Analyst, Industry & Technology Research |
|
|
|
|
|
| Japan's private capital dealmaking shines despite fundraising slowdown |
|
Japan's private capital markets continue to defy global sluggishness, maintaining strong deal flow across PE and VC even as fundraising cools, according to the 2025 Japan Private Capital Breakdown.
At the heart of this resilience is Japan's uniquely supportive financing landscape. Even as the Bank of Japan began gradually easing in 2024, leveraged buyout loans remained among the lowest in the developed world at around 3% to 4%. A persistently weak yen further boosted dollar-based returns, giving nondomestic sponsors an added lift and widening Japan's appeal as a buyout destination.
Corporate reform is powering the pipeline. Governance pressures and the Tokyo Stock Exchange's campaign for capital efficiency have pushed conglomerates to streamline portfolios. Carveout deal value rebounded to $4.1 billion, while take-private transactions have exceeded 25% of PE deal value for six straight years—clear signs that divestments and privatizations remain central engines of activity.
Succession dynamics are adding another engine. Roughly one-third of Japan's SMEs are owned by founders over 70 without clear successors, creating a steady flow of middle-market opportunities where PE firms step in to support leadership transitions and modernization.
Venture dealmaking has been equally resilient. Late-stage deals have nearly doubled their share since 2016, reaching 45%, underscoring the rapid maturation of Japan's startup ecosystem. Software and business-to-consumer are the dominant verticals as corporates continue to accelerate digital transformation and shift to subscription-based models.
Fundraising is the one clear weak spot. Japan-focused GPs have raised just $2.6 billion YTD, down sharply from $12.2 billion in 2024, with only two funds exceeding $500 million. LP caution mirrors global trends, with capital flowing primarily toward thematic strategies.
Even so, Japan's private markets will continue to punch above their weight, as long as structural drivers remain intact. A rebound in fundraising could unlock a fresh wave of capital, allowing Japan's already-robust deal flow to accelerate into 2026.
For more data, download the report, which is available in English and Japanese.
|
|
Have a great weekend,
Ansel Tan
Director, APAC Private Capital |
|
|
|
|
|
| |
|
|
Pharma Biotools VC Trends
The pharma biotools sector—which encompasses technologies and services for drug discovery, clinical development, diagnostics, and biopharmaceutical manufacturing—is on pace for 513 VC deals in 2025, compared with a prior annual average of 399 since 2020. |
|
Seed-stage startups have accounted for a record 18% of total capital deployed YTD, as investment is heavily weighted toward emerging technologies rather than mature startups.
AI integration into biotech has been a major driver of the uptick, as computational tools and emerging biological foundation models continue to attract significant capital.
Lila Sciences, pursuing "scientific superintelligence" through autonomous labs, raised a $350 million Series A at a $1.3 billion valuation. Chai Discovery raised $70 million at a $573 million valuation for its de novo antibody design model. Other notable deals and areas of investment in Q3 included the synthetic biology & CRISPR category, headlined by Colossal Biosciences' $120 million Series C extension.
Read the report |
|
|
|
|
|
Gaming VC Activity in Emerging Markets
Gaming's center of gravity is shifting. Our latest analyst note shows emerging markets—home to 86% of the world's population—now account for around 15% of global gaming revenue, up from 4% in 2010.
Case studies like China's Tencent and NetEase Games, Singapore's Sea Limited, and South Korea's Krafton highlight how mobile-first expertise is scaling into the PC and console market and the value of franchise intellectual property.
The growth engines: the Middle East & North Africa, Latin America, India, and Southeast Asia—regions benefiting from affordable smartphones, rising digital payments, and favorable demographics—are pushing toward 5% to 6% of global gaming revenue.
Tailwinds include regulatory enablement and lower production costs; headwinds remain around monetization, banking access, and policy volatility (notably in India and China).
Bottom line: While the US and Europe see growth in the low-to-mid single digits, emerging markets can double that pace—and could contribute the majority of global gaming revenue by 2030.
Read the report |
|
|
|
|
|
| |
|
|
Dec. 9: Analysts from PitchBook and Morningstar will discuss key considerations for evergreen funds as these vehicles become part of the allocator toolkit. Register for the webinar here.
January-February: Our new global outlook series is coming to London, Singapore, New York and San Francisco. These events will bring global thought leaders to | | | | | | |